Dolby Laboratories (NYSE:DLB)'s stock had its "buy" rating reissued by equities researchers at Tigress Financial in a note issued to investors on Thursday, AnalystRatings.com reports.
Several other analysts also recently commented on DLB. Barrington Research downgraded Dolby Laboratories from an "outperform" rating to a "market perform" rating in a research note on Tuesday, January 26th. Zacks Investment Research raised Dolby Laboratories from a "sell" rating to a "hold" rating and set a $98.00 price target on the stock in a research note on Tuesday. Finally, B. Riley lifted their price target on Dolby Laboratories from $79.00 to $89.00 and gave the company a "neutral" rating in a research note on Friday, January 29th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Dolby Laboratories has a consensus rating of "Hold" and a consensus target price of $83.75.
Shares of Dolby Laboratories stock opened at $96.88 on Thursday. The company has a market capitalization of $9.84 billion, a PE ratio of 43.06, a PEG ratio of 3.27 and a beta of 0.89. Dolby Laboratories has a 12 month low of $44.68 and a 12 month high of $97.78. The stock's fifty day simple moving average is $93.35 and its 200 day simple moving average is $81.74.
Dolby Laboratories (NYSE:DLB) last issued its quarterly earnings data on Thursday, January 28th. The electronics maker reported $1.48 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.86 by $0.62. The business had revenue of $389.87 million for the quarter, compared to the consensus estimate of $345.33 million. Dolby Laboratories had a return on equity of 9.89% and a net margin of 19.91%. The firm's revenue was up 33.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.64 EPS. Equities research analysts predict that Dolby Laboratories will post 2.24 EPS for the current fiscal year.
In other news, SVP Steven E. Forshay sold 834 shares of the firm's stock in a transaction dated Wednesday, December 16th. The stock was sold at an average price of $92.00, for a total value of $76,728.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin J. Yeaman sold 11,539 shares of the firm's stock in a transaction dated Wednesday, December 16th. The shares were sold at an average price of $90.76, for a total value of $1,047,279.64. The disclosure for this sale can be found here. Insiders sold a total of 179,044 shares of company stock valued at $16,451,164 in the last 90 days. 37.30% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. NEXT Financial Group Inc grew its holdings in shares of Dolby Laboratories by 69.2% in the 4th quarter. NEXT Financial Group Inc now owns 269 shares of the electronics maker's stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Harvest Fund Management Co. Ltd grew its holdings in Dolby Laboratories by 47.5% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 534 shares of the electronics maker's stock worth $51,000 after purchasing an additional 172 shares during the period. CI Investments Inc. bought a new position in Dolby Laboratories during the third quarter worth about $36,000. TD Ameritrade Investment Management LLC bought a new position in Dolby Laboratories during the fourth quarter worth about $54,000. Finally, Exchange Traded Concepts LLC grew its holdings in Dolby Laboratories by 497.4% during the fourth quarter. Exchange Traded Concepts LLC now owns 693 shares of the electronics maker's stock worth $67,000 after purchasing an additional 577 shares during the period. Institutional investors own 58.58% of the company's stock.
Dolby Laboratories Company Profile
Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment and communications at the cinema, at home, at work, and on mobile devices. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications.; AVC, a digital video codec with high bandwidth efficiency used in media devices; Dolby AC-4, an audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and a range of media devices.
See Also: What’s a Black Swan?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Healthcare Stocks Delivering Innovation in 2021
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.
View the "7 Healthcare Stocks Delivering Innovation in 2021".